Vanda Pharmaceuticals | VNDA - Ingresos Por Ventas

Precio De Mercado
7.89
Cambio Diario
-0.31 -3.78%
Mensual
9.13%
Anual
53.80%
Q1 Expectativa
8.64




Ventas Cambio Fecha
Acadia Pharmaceuticals USD 284M 5.4M 2025-12
Agios Pharmaceuticals USD 19.97M 7.07M 2025-12
Akebia Therapeutics USD 57.34M 10.84M 2025-03
Alnylam Pharmaceuticals USD 1.1B 150M 2025-12
Anika Therapeutics USD 26.17M 12.58M 2025-03
Arrowhead Research USD 264.03M 7.56M 2025-12
AstraZeneca USD 15.5B 313M 2025-12
Bristol-Myers Squibb USD 12.5B 300M 2025-12
Eli Lilly USD 19.3B 1.7B 2025-12
Enanta Pharmaceuticals USD 16.96M 50.68M 2024-12
Esperion Therapeutics USD 51.63M 22.2M 2024-09
Halozyme Therapeutics USD 451.76M 97.76M 2025-12
Heron Therapeutics USD 32.81M 3.21M 2024-09
Insmed USD 263.8M 121.8M 2025-12
J&J USD 24.6B 610M 2025-12
Lexicon Pharmaceuticals USD 1.65M 520K 2024-06
Ligand Pharmaceuticals USD 59.66M 55.8M 2025-12
Merck USD 16.4B 880M 2025-12
Minerva Neurosciences USD 0 0 2024-09
Moderna USD 678M 342M 2025-12
Novartis USD 14.36B 478M 2025-09
Pfizer USD 17.58B 880M 2025-12
PTC Therapeutics USD 164.7M 46.3M 2025-12
Puma Biotechnology USD 80.54M 33.46M 2024-09
Sangamo BioSciences USD 356K 125K 2024-06
Sanofi EUR 11.3B 1.13B 2025-12
Takeda JPY 1.19T 80B 2025-12
Teva Pharmaceutical Industries USD 14.63B 10M 2025-12
Ultragenyx Pharmaceutical USD 207M 47M 2025-12
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12
Veracyte USD 140.6M 8.7M 2025-12